JUN and liver cancer: Furthermore, inhibiting the METTL3-mediated activation of frizzled10 in liver cancer cells contributes to lenvatinib resistance by regulating the downstream β-catenin/c-Jun/Mitogen-activated protein kinase kinase (MEK)/ERK axis [98].